Phaseline

Companies › Shanghai JMT-Bio

Shanghai JMT-Bio: clinical trials, targets and expected readouts

11 active drug programs in 19 registered trials: 8 Phase 1, 7 Phase 3, 4 Phase 2; Oncology, Other, Metabolic and endocrine; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Kn-026 (KN026)
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Early or Locally Advanced HER2-positive Breast Cancer; First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer; Resectable HER2-positive Breast Cancer; Stomach Cancer …Nov 2026
JMT101
Anti-EGFR monoclonal antibody
EGFRPhase 3Locally Advanced or Metastatic Non-squamous NSCLC; Local Advanced or Metastatic NSCLCNov 2026
Osimertinib mesylate
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Non-Small Cell Lung Cancer; Local Advanced or Metastatic NSCLCNov 2026
Glumetinib
MEK inhibitor
MAP2K1Phase 3Non-Small Cell Lung CancerFeb 2028
JSKN003
HER2-targeted antibody-drug conjugate
–Phase 3Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer ParticipantsDec 2028
JMT108
unclear mechanism
–Phase 1Unresectable Locally Advanced or Metastatic Melanoma; Advanced Malignant TumorsNov 2026
JMT206
GLP-1 receptor agonist
–Phase 1Healthy Participants; Valid MeSH ConditiongsFeb 2027
JMT203 Injection
anti-GFRAL monoclonal antibody
GFRALPhase 1Non Small Cell Lung CancerAug 2027
JMT106 Injection–Phase 1Advanced Solid TumorNov 2028
JMT202 injection–Phase 1Hypertriglyceridemia–
JMT601
anti-CD20 monoclonal antibody
MS4A1Phase 1B-cell Non Hodgkin Lymphoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06725524JMT601Phase 1B-cell Non Hodgkin LymphomaOncologyDec 2025
NCT07140809JMT202 injectionPhase 1HypertriglyceridemiaMetabolic and endocrineJul 2026
NCT07419698JMT206Phase 1Healthy ParticipantsOtherSep 2026
NCT05427383Kn-026 (KN026)Phase 2Stomach CancerOncologyNov 2026
NCT06391944JMT101Phase 2Local Advanced or Metastatic NSCLCOncologyNov 2026
NCT06391944Osimertinib mesylatePhase 2Local Advanced or Metastatic NSCLCOncologyNov 2026
NCT07280832JMT108Phase 1Unresectable Locally Advanced or Metastatic MelanomaOncologyNov 2026
NCT06747338Kn-026 (KN026)Phase 3Early or Locally Advanced HER2-positive Breast CancerOncologyDec 2026
NCT06023758Kn-026 (KN026)Phase 2HER2-positive Locally Advanced Resectable Gastric CancerOncologyDec 2026
NCT07840729JMT206Phase 1Valid MeSH ConditiongsOtherFeb 2027
NCT06868849JMT203 InjectionPhase 1Non Small Cell Lung CancerOncologyAug 2027
NCT05838066Kn-026 (KN026)Phase 3First-line Treatment of HER2-positive Recurrent or Metastatic Breast CancerOncologyDec 2027
NCT06829459GlumetinibPhase 3Non-Small Cell Lung CancerOncologyFeb 2028
NCT06829459Osimertinib mesylatePhase 3Non-Small Cell Lung CancerOncologyFeb 2028
NCT06877650JMT108Phase 1Advanced Malignant TumorsOncologyMar 2028
NCT07275073JMT106 InjectionPhase 1Advanced Solid TumorOncologyNov 2028
NCT06846437JSKN003Phase 3Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer ParticipantsOncologyDec 2028
NCT06735391JMT101Phase 3Locally Advanced or Metastatic Non-squamous NSCLCOncologyMay 2029
NCT07441460Kn-026 (KN026)Phase 3Resectable HER2-positive Breast CancerOncologyAug 2034

Targets

EGFR (2) ERBB2 (1) GFRAL (1) MS4A1 (1) MAP2K1 (1)

Companies with the same targets

Roche Beijing Biotech AstraZeneca Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Yuhan Pfizer Jiangsu HengRui Medicine Allist Pharmaceuticals

Companies built like this

Pierre Fabre Medicament DualityBio Jiangsu Alphamab Biopharmaceuticals R-Pharm BioRay Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.